AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
| Revenue (TTM) | $61.37B |
| Gross Profit (TTM) | $50.13B |
| EBITDA | $19.90B |
| Operating Margin | 23.50% |
| Return on Equity | 22.00% |
| Return on Assets | 8.02% |
| Revenue/Share (TTM) | $39.59 |
| Book Value | $32.43 |
| Price-to-Book | 4.82 |
| Price-to-Sales (TTM) | 3.96 |
| EV/Revenue | 4.351 |
| EV/EBITDA | 13.12 |
| Quarterly Earnings Growth (YoY) | 2.50% |
| Quarterly Revenue Growth (YoY) | 6.40% |
| Shares Outstanding | $1.55B |
| Float | $1.54B |
| % Insiders | 0.05% |
| % Institutions | 65.47% |
Volatility is currently contracting
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has retained a 'buy' rating from Citi following a mixed set of pipeline updates, with the broker saying its underlying investment thesis remains unchanged and that the drugmaker continues to offer the strongest growth and pipeline profile in the sector. Citi highlighted positive results from the Phase III SAFFRON trial, where Tagrisso plus Orpathys met the primary endpoint and demonstrated statistically significant and clinically meaningful progression-free survival and overall survival benefits against platinum-doublet chemotherapy in second-line EGFR-mutated, MET-driven non-small cell lung cancer.
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in combination with AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Tagrisso in patients with a form of non-small cell lung cancer whose disease had worsened despite treatment.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported positive results from a late-stage trial of a two-drug combination for a hard-to-treat form of lung cancer, potentially opening the way to approval around the world. The study tested the company's established lung cancer pill Tagrisso alongside a newer drug called Orpathys, developed with the Hong Kong-based biotech HUTCHMED.
The decision was based on the recommendation of the Independent Data Monitoring Committee, which said volrustomig plus chemotherapy was unlikely to reach primary endpoints.
AstraZeneca on Monday said it is discontinuing a late stage trial that tested volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.
Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion.
Investors need to pay close attention to AZN stock based on the movements in the options market lately.
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and integration risk. The reports had the industry thinking about a kind of dealmaking it has avoided for more than a decade.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZN and any ticker you trade — then tracks every position and per-strategy win rate.
